Intrinsically safe leak detection empowers our hydrogen-powered future

Leak detection

Intrinsically safe leak detection empowers our hydrogen-powered future

11 Aug, 2025

The world is shifting toward hydrogen-powered clean energy systems; ensuring safe, rapid leak detection in critical environments is critical. INFICON’s Extrima® is a high-performance, intrinsically safe hydrogen leak detector built for hazardous Zone 0 environments (Ex ia IIC T3), and certified by ATEX, IECEx, TIIS, NEPSI, and CSA.

Extrima® has been designed for environmental and industrial sectors focused on zero-carbon solutions. Extrima offers exceptional sensitivity: detecting leaks as small as 0.5 ppm or 5 × 10⁷ cc/s using forming gas, even faster and more precisely when deployed with pure hydrogen. These performance levels are ideal for maintaining integrity in fuel cell systems, hydrogen infrastructure, power generation, and aerospace applications.

The resilient Extrima is IP67-rated, battery-powered for more than 7 hours of continuous use, and operable in the harshest industrial conditions. In demanding sectors, including aerospace and power generation, Extrima has proven its ability to reduce leak-identification and repair times by over 50%, boosting both operational efficiency as well as environmental safety.

INFICON Extrima® delivers a considerable technological leap for hydrogen leak detection, combining intrinsic safety, sensitivity, and usability to facilitate safe deployment of hydrogen systems at scale.

Latest News

IET Guide 2026

Explore our Digital Edition

Discover the latest news and research

Digital edition

Explore Our Other Sites

Labmate Online
Portable fluorescence reader could bring forward molecular tests for use at home
Explore more Arrow
Pollution Solutions Online
Leading UK biogas operator places first orders for new FlowSep technology
Explore more Arrow
Petro Online
Vietnam’s E10 rollout puts fuel testing capacity under closer scrutiny
Explore more Arrow
Chromatography Today
Unlock high-resolution analysis of therapeutic oligonucleotides
Explore more Arrow